Driving Gross-to-Net Excellence and Portfolio Expansion in Mid-Market Pharma

During a standard executive business review (EBR) with a $1B oncolytics manufacture, IntegriChain learned that their customer planned to expand into a new therapeutic category, dermatology. Entering a new category meant moving from smaller data volumes, fewer price concessions, and less government pricing (GP) and gross-to-net (GTN) complexity, to a dermatology therapy with highly complex commercial contracting, more variables in GP calculations, more line items in GTN analysis, and an order of magnitude more data volume. Find out more how IntegriChain helped by downloading the case study. Download below!